The trial attained the two its Principal endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and outstanding enhancements in liver fibrosis without having worsening of steatohepatitis, and also resolution of steatohepatitis without having worsening of liver fibrosis in people